Mersana Therapeutics (NASDAQ:MRSN – Free Report) had its price objective trimmed by Robert W. Baird from $4.00 to $3.00 in a report published on Wednesday morning, Benzinga reports. The firm currently has a neutral rating on the stock.
Separately, Lifesci Capital raised Mersana Therapeutics to a strong-buy rating in a report on Monday, July 29th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Mersana Therapeutics currently has a consensus rating of Moderate Buy and a consensus price target of $6.00.
Read Our Latest Analysis on MRSN
Mersana Therapeutics Price Performance
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The company had revenue of $2.30 million for the quarter, compared to the consensus estimate of $8.72 million. Mersana Therapeutics had a negative net margin of 352.01% and a negative return on equity of 260.65%. The company’s quarterly revenue was down 78.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.47) EPS. As a group, sell-side analysts anticipate that Mersana Therapeutics will post -0.6 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in MRSN. Russell Investments Group Ltd. lifted its position in Mersana Therapeutics by 976.7% in the first quarter. Russell Investments Group Ltd. now owns 9,453 shares of the company’s stock worth $42,000 after buying an additional 8,575 shares during the last quarter. Victory Capital Management Inc. bought a new position in Mersana Therapeutics during the fourth quarter valued at $30,000. Nisa Investment Advisors LLC raised its stake in shares of Mersana Therapeutics by 479.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 17,643 shares of the company’s stock valued at $41,000 after acquiring an additional 14,600 shares during the period. Walleye Trading LLC bought a new stake in shares of Mersana Therapeutics in the 1st quarter worth about $141,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth about $226,000. Institutional investors own 93.92% of the company’s stock.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Recommended Stories
- Five stocks we like better than Mersana Therapeutics
- Why Are Stock Sectors Important to Successful Investing?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Walmart Stock: Buy the Rip or Wait for the Dip?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Stocks to Buy for a Soft Landing, If There Is One
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.